DE60217507D1 - Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern - Google Patents

Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern

Info

Publication number: DE60217507D1
Authority: DE; Germany
Prior art keywords: peptides; removal; cells; tumors; destroying
Prior art date: 2001-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60217507T

Other languages

English (en)

Other versions

DE60217507T2 (de

Inventor

A Averback

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nymox Corp

Original Assignee

Nymox Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-19

Filing date

2002-07-19

Publication date

2007-02-22

2002-07-19 Application filed by Nymox Corp filed Critical Nymox Corp

2007-02-22 Publication of DE60217507D1 publication Critical patent/DE60217507D1/de

2007-11-15 Application granted granted Critical

2007-11-15 Publication of DE60217507T2 publication Critical patent/DE60217507T2/de

2022-07-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Surgery (AREA)
Virology (AREA)

DE60217507T 2001-07-19 2002-07-19 Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern Expired - Lifetime DE60217507T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US30615001P	2001-07-19	2001-07-19
US30616101P	2001-07-19	2001-07-19
US306150P		2001-07-19
US306161P		2001-07-19
US33147701P	2001-11-16	2001-11-16
US331477P		2001-11-16
PCT/CA2002/001105 WO2003008443A2 (en)	2001-07-19	2002-07-19	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (2)

Publication Number	Publication Date
DE60217507D1 true DE60217507D1 (de)	2007-02-22
DE60217507T2 DE60217507T2 (de)	2007-11-15

Family

ID=27405149

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60217507T Expired - Lifetime DE60217507T2 (de)	2001-07-19	2002-07-19	Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
DE60218179T Expired - Lifetime DE60218179T2 (de)	2001-07-19	2002-07-19	Peptide zur behandlung von tumoren und anderen bedingungen, die die entfernung oder zerstörung von zellen erfordern

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60218179T Expired - Lifetime DE60218179T2 (de)	2001-07-19	2002-07-19	Peptide zur behandlung von tumoren und anderen bedingungen, die die entfernung oder zerstörung von zellen erfordern

Country Status (22)

Country	Link
US (2)	US7192929B2 (de)
EP (2)	EP1417228B1 (de)
JP (4)	JP4587667B2 (de)
KR (2)	KR100966232B1 (de)
CN (1)	CN100475843C (de)
AT (1)	ATE353914T1 (de)
AU (2)	AU2002319050B2 (de)
BR (2)	BRPI0211200B8 (de)
CA (2)	CA2453967C (de)
CY (1)	CY1108009T1 (de)
DE (2)	DE60217507T2 (de)
DK (1)	DK1417228T3 (de)
EA (1)	EA006603B1 (de)
ES (2)	ES2281528T3 (de)
IL (2)	IL159903A0 (de)
MX (1)	MXPA04000561A (de)
NO (1)	NO333999B1 (de)
NZ (2)	NZ531114A (de)
PL (1)	PL207588B1 (de)
PT (1)	PT1417228E (de)
WO (2)	WO2003008443A2 (de)
ZA (1)	ZA200401320B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050245451A1 (en) *	2000-04-05	2005-11-03	Pincus Matthew R	Peptides selectively lethal to malignant and transformed mammalian cells
DE60222745T2 (de) *	2001-03-08	2008-07-10	Nymox Pharmaceutical Corp., St. Laurent	Verwendung von neurofilamentproteinen zur behandlung von tumoren
US7271240B2 (en)	2001-03-14	2007-09-18	Agensys, Inc.	125P5C8: a tissue specific protein highly expressed in various cancers
EA006603B1 (ru) *	2001-07-19	2006-02-24	Наймокс Корпорейшн	Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
US7317077B2 (en) *	2001-11-16	2008-01-08	Nymox Pharmaceutical Corporation	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2002359572A1 (en) *	2001-12-04	2003-06-17	Millennium Pharmaceuticals, Inc.	15603, a human ion channel family member
EP1644017A2 (de) *	2003-07-15	2006-04-12	National Research Council Of Canada	Cyclische analoga des humanen parahormons zur behanldung von erkrankungen, die durch hyperproliferative hautzellen charakterisiert sind
US20080227125A1 (en) *	2003-07-15	2008-09-18	Guilaine Argoud-Puy	Secreted Polypeptide Species Reduced in Cardiovascular Disorders
CN1965082A (zh) *	2004-02-06	2007-05-16	尼莫克斯股份有限公司	人源化抗体
US20060173490A1 (en)	2005-02-01	2006-08-03	Boston Scientific Scimed, Inc.	Filter system and method
DK1994152T3 (da)	2006-02-28	2013-03-11	Nymox Corp	Peptider der er effektive i behandlingen af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler
BRPI0708737A2 (pt) *	2006-03-10	2011-06-14	Nymox Corp	mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural
US20080027005A1 (en) *	2006-07-31	2008-01-31	Paul Averback	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
JP5572938B2 (ja) *	2007-10-25	2014-08-20	東レ株式会社	免疫誘導剤
CA2990255C (en) *	2007-10-25	2023-01-10	Toray Industries, Inc.	Immune response inducer
US9539327B2 (en) *	2007-11-26	2017-01-10	The Research Foundation For The State University Of New York	Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
EP2293809B1 (de) *	2008-04-24	2019-05-15	Therimunex Pharmaceuticals, Inc.	Peptidyldiacylglyceride
KR101851746B1 (ko)	2010-09-29	2018-04-24	어젠시스 인코포레이티드	191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
RU2016117275A (ru)	2013-11-01	2017-12-04	Сфериум Биомед С.Л.	Тельца включения для трансдермальной доставки терапевтических и косметических средств
US20160215031A1 (en) *	2015-01-27	2016-07-28	Nymox Pharnaceutical Corporation	Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en)	2015-06-12	2016-12-15	Nymox Corporation	Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en)	2015-07-24	2023-04-18	Nymox Corporation	Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en)	2016-06-17	2019-01-22	Nymox Corporation	Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) *	2016-07-28	2019-01-08	Nymox Corporation	Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en)	2016-09-07	2020-01-14	Nymox Corporation	Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en)	2017-03-01	2019-07-02	Nymox Corporation	Compositions and methods for improving sexual function
US10835538B2 (en)	2018-03-28	2020-11-17	Nymox Corporation	Method of treating benign prostatic hyperlasia with antibiotics
US12239720B2 (en)	2018-04-06	2025-03-04	Oncolyze, Inc.	Compositions for use in lysis of selective cancer cells
US20200061150A1 (en)	2018-08-23	2020-02-27	Nymox Corporation	Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
AR117652A1 (es)	2018-12-03	2021-08-25	Agensys Inc	Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
US11278588B2 (en)	2019-05-13	2022-03-22	Nymox Corporation	Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en)	2019-05-13	2020-11-19	Nymox Corporation	Method of improving lower urinary tract symptoms
US11298400B2 (en)	2019-05-13	2022-04-12	Nymox Corporation	Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en)	2019-07-31	2022-05-17	Nymox Corporation	Focal treatment of prostate cancer
US11231421B2 (en)	2019-07-31	2022-01-25	Nymox Corporation	Methods of treating multifocal cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5948634A (en) *	1988-12-21	1999-09-07	The General Hospital Coporation	Neural thread protein gene expression and detection of alzheimer's disease
JP3309972B2 (ja)	1988-12-21	2002-07-29	ザ・ジェネラル・ホスピタル・コーポレイション	神経系疾患または機能障害の検出法
JP4194664B2 (ja) *	1997-02-26	2008-12-10	ザジェネラルホスピタルコーポレイション	アルツハイマー病の処置または予防のために効果的な薬物をスクリーニングするためのトランスジェニック動物および細胞株
CA2335986A1 (en) *	1998-06-26	2000-01-06	Simeng Suy	Use of tempo and tempo derivatives for inducing cell death
AU2185199A (en) *	1998-09-30	2000-04-17	Yoko Aida	Apoptosis inducers
EP1135494A2 (de) *	1998-12-11	2001-09-26	Incyte Pharmaceuticals, Inc.	Mit neuronen assoziierte proteine
DK1143994T3 (da) *	1999-01-11	2003-10-20	Leadd Bv	Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme
CA2364630A1 (en)	1999-03-12	2000-09-21	Human Genome Sciences, Inc.	50 human secreted proteins
JP2002543764A (ja) *	1999-03-19	2002-12-24	ヒューマンジノームサイエンシーズ，インコーポレイテッド	４６個のヒト分泌タンパク質
JP2002541833A (ja)	1999-03-26	2002-12-10	ヒューマンジノームサイエンシーズ，インコーポレイテッド	４９個のヒト分泌タンパク質
JP2003535570A (ja) *	1999-03-26	2003-12-02	ヒューマンジノームサイエンシーズ，インコーポレイテッド	５０個のヒト分泌タンパク質
AU3769700A (en) *	1999-03-26	2000-10-16	Human Genome Sciences, Inc.	45 human secreted proteins
CN1300779A (zh)	1999-12-22	2001-06-27	上海博德基因开发有限公司	一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh)	1999-12-23	2001-06-27	上海生元基因开发有限公司	新的人神经元线蛋白及其编码序列
WO2002000718A2 (en) *	2000-06-26	2002-01-03	Millennium Pharmaceuticals, Inc.	A human calcium channel protein and uses thereof
CN1352145A (zh) *	2000-11-10	2002-06-05	上海博德基因开发有限公司	一种新的多肽——锌指蛋白14.08和编码这种多肽的多核苷酸
US6783969B1 (en) *	2001-03-05	2004-08-31	Nuvelo, Inc.	Cathepsin V-like polypeptides
DK1390403T3 (da)	2001-05-25	2007-05-14	Nymox Corp	Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
EA006603B1 (ru) *	2001-07-19	2006-02-24	Наймокс Корпорейшн	Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток

2002
- 2002-07-19 EA EA200400205A patent/EA006603B1/ru unknown
- 2002-07-19 CN CNB028164903A patent/CN100475843C/zh not_active Expired - Fee Related
- 2002-07-19 WO PCT/CA2002/001105 patent/WO2003008443A2/en not_active Ceased
- 2002-07-19 EP EP02748517A patent/EP1417228B1/de not_active Expired - Lifetime
- 2002-07-19 PL PL368912A patent/PL207588B1/pl unknown
- 2002-07-19 CA CA2453967A patent/CA2453967C/en not_active Expired - Lifetime
- 2002-07-19 AT AT02748517T patent/ATE353914T1/de active
- 2002-07-19 JP JP2003514002A patent/JP4587667B2/ja not_active Expired - Lifetime
- 2002-07-19 KR KR1020047000844A patent/KR100966232B1/ko not_active Expired - Lifetime
- 2002-07-19 ES ES02748516T patent/ES2281528T3/es not_active Expired - Lifetime
- 2002-07-19 IL IL15990302A patent/IL159903A0/xx unknown
- 2002-07-19 US US10/198,069 patent/US7192929B2/en not_active Expired - Fee Related
- 2002-07-19 AU AU2002319050A patent/AU2002319050B2/en not_active Expired
- 2002-07-19 WO PCT/CA2002/001106 patent/WO2003008444A2/en not_active Ceased
- 2002-07-19 MX MXPA04000561A patent/MXPA04000561A/es active IP Right Grant
- 2002-07-19 BR BRPI0211200A patent/BRPI0211200B8/pt not_active IP Right Cessation
- 2002-07-19 KR KR1020047000843A patent/KR101005130B1/ko not_active Expired - Fee Related
- 2002-07-19 DE DE60217507T patent/DE60217507T2/de not_active Expired - Lifetime
- 2002-07-19 NZ NZ531114A patent/NZ531114A/en not_active IP Right Cessation
- 2002-07-19 BR BR0211199-3A patent/BR0211199A/pt not_active IP Right Cessation
- 2002-07-19 PT PT02748517T patent/PT1417228E/pt unknown
- 2002-07-19 JP JP2003514001A patent/JP2005507647A/ja active Pending
- 2002-07-19 NZ NZ531115A patent/NZ531115A/en not_active IP Right Cessation
- 2002-07-19 ES ES02748517T patent/ES2281529T3/es not_active Expired - Lifetime
- 2002-07-19 DE DE60218179T patent/DE60218179T2/de not_active Expired - Lifetime
- 2002-07-19 US US10/198,070 patent/US7241738B2/en not_active Expired - Lifetime
- 2002-07-19 CA CA2453965A patent/CA2453965C/en not_active Expired - Fee Related
- 2002-07-19 EP EP02748516A patent/EP1417227B1/de not_active Expired - Lifetime
- 2002-07-19 DK DK02748517T patent/DK1417228T3/da active
- 2002-07-19 AU AU2002319049A patent/AU2002319049B2/en not_active Ceased
2004
- 2004-01-15 IL IL159903A patent/IL159903A/en active IP Right Grant
- 2004-01-16 NO NO20040222A patent/NO333999B1/no not_active IP Right Cessation
- 2004-02-18 ZA ZA2004/01320A patent/ZA200401320B/en unknown
2007
- 2007-04-26 CY CY20071100553T patent/CY1108009T1/el unknown
2011
- 2011-02-22 JP JP2011035954A patent/JP2011152133A/ja active Pending
2013
- 2013-04-04 JP JP2013078281A patent/JP5622885B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2011152133A (ja)	2011-08-11
KR20040026686A (ko)	2004-03-31
NZ531114A (en)	2006-12-22
JP2013215191A (ja)	2013-10-24
KR100966232B1 (ko)	2010-06-25
ATE353914T1 (de)	2007-03-15
JP2005507647A (ja)	2005-03-24
CA2453965C (en)	2016-01-19
JP2005506061A (ja)	2005-03-03
WO2003008444A3 (en)	2003-11-20
CY1108009T1 (el)	2013-09-04
CN1649895A (zh)	2005-08-03
WO2003008443A3 (en)	2003-11-27
AU2002319049B2 (en)	2007-10-25
KR101005130B1 (ko)	2011-01-04
MXPA04000561A (es)	2005-02-17
CA2453965A1 (en)	2003-01-30
DE60217507T2 (de)	2007-11-15
DE60218179D1 (de)	2007-03-29
IL159903A0 (en)	2004-06-20
AU2002319050B2 (en)	2008-09-11
EA006603B1 (ru)	2006-02-24
NO20040222L (no)	2004-03-19
US7241738B2 (en)	2007-07-10
BR0211200A (pt)	2004-09-28
KR20040018481A (ko)	2004-03-03
US20030096756A1 (en)	2003-05-22
ZA200401320B (en)	2005-01-26
EA200400205A1 (ru)	2004-06-24
PT1417228E (pt)	2007-05-31
CN100475843C (zh)	2009-04-08
PL207588B1 (pl)	2011-01-31
PL368912A1 (en)	2005-04-04
JP4587667B2 (ja)	2010-11-24
CA2453967A1 (en)	2003-01-30
US20030109437A1 (en)	2003-06-12
EP1417227B1 (de)	2007-01-10
BR0211199A (pt)	2004-10-26
NZ531115A (en)	2005-03-24
ES2281529T3 (es)	2007-10-01
JP5622885B2 (ja)	2014-11-12
US7192929B2 (en)	2007-03-20
NO333999B1 (no)	2013-11-11
IL159903A (en)	2010-02-17
EP1417228B1 (de)	2007-02-14
DK1417228T3 (da)	2007-06-04
BRPI0211200B1 (pt)	2020-03-17
BRPI0211200B8 (pt)	2021-07-27
WO2003008444A2 (en)	2003-01-30
ES2281528T3 (es)	2007-10-01
EP1417227A2 (de)	2004-05-12
EP1417228A2 (de)	2004-05-12
CA2453967C (en)	2014-01-07
WO2003008443A2 (en)	2003-01-30
DE60218179T2 (de)	2007-11-22

Publication	Publication Date	Title
DE60217507D1 (de)	2007-02-22	Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
DE60213274D1 (de)	2006-08-31	Peptide zum einsatz in der behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
CY1111120T1 (el)	2015-06-11	Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
ATE326239T1 (de)	2006-06-15	Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
EA200200755A1 (ru)	2002-12-26	Опосредованная рецептором nogo блокада роста аксонов
DK1368054T3 (da)	2008-02-04	Anvendelse af neurale trådproteiner til behandling af tumorer
ATE326981T1 (de)	2006-06-15	Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE401400T1 (de)	2008-08-15	Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
WO2008014603A3 (en)	2008-05-15	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE313561T1 (de)	2006-01-15	Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60234843D1 (de)	2010-02-04	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
WO2005034844A3 (en)	2005-09-22	Exosite-directed thrombin inhibitors
EP1714979A3 (de)	2007-04-25	Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern
DE602004025017D1 (de)	2010-02-25	C1ckb-mutation als diagnostisches und therapeutisches ziel
EP1847550A3 (de)	2008-01-09	Peptide zur effektiven Behandlung von Tumoren und anderen Bedingungen, die Zellentfernung oder- zerstörung erfordern
AR037054A1 (es)	2004-10-20	Composiciones y metodos de diagnostico y terapia de cancer de pulmon

Legal Events

Date	Code	Title	Description
2008-01-31	8364	No opposition during term of opposition